Download Slide 1

Who we are –
DPAc represents a new approach to early drug discovery. The concept is simple but
powerful: bring together the insight and creativity of the academic world with the drug
discovery expertise of GlaxoSmithKline (GSK). We are a dedicated team of experienced drug
discovery scientists – internal champions for your project and a gateway to the global
resources of GSK. Our goal is to establish truly integrated partnerships that can translate
innovative research into medicines that benefit patients.
Who you are –
An academic partner with the unique know-how and key expertise that is essential for the
successful progression of a drug target. You are a researcher who wants to see their
innovative ideas turned into a medicine.
What are we looking for?
1. A coherent therapeutic hypothesis based on sound understanding of patho-mechanism in
any disease area.
2. A defined drug target with understanding of the pharmacology (e.g. antagonist, agonist)
and link to the disease.
3. Bioassays that can be adapted to the high throughput screening modes necessary to
support drug discovery.
4. We are not able to consider drug re-purposing efforts, biomarker strategies or novel
discovery platforms.
What do we offer?
1. If selected, funding to support collaborative discovery research including additional
target validation and high throughput screening at GSK facilities.
Link to DPAc Website
http://www.dpac.gsk.com/
Link to case studies
http://www.openinnovation.gsk.com/proven.php
Proposals should be submitted to:
Peter Kotsonis ([email protected]) in the Office of Innovation,
Technology & Alliances by July 25th, 2016